Journal
EMERGING INFECTIOUS DISEASES
Volume 27, Issue 11, Pages 2878-2881Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2711.210636
Keywords
-
Categories
Funding
- Sociedade Francisco Manuel dos Santos and Grupo Jeronimo Martins
- LANL LDRD Program [20210730ER]
- Fundacao para a Ciencia e Tecnologia (Portugal) [PTDC/MAT-APL/31602/2017, UID/MAT/00006/2019]
- European Union Horizon 2020 Research and Innovation Program [952377]
- European Union H2020 ERA project [667824]
- Sociedade Francisco Manuel dos Santos
- Grupo Jeronimo Martins
- Fundação para a Ciência e a Tecnologia [PTDC/MAT-APL/31602/2017] Funding Source: FCT
Ask authors/readers for more resources
A study conducted in Portugal in September 2020 found a seroprevalence of 2.2% for antibodies against the coronavirus, which was 3-4 times larger than the official number of cases at the end of the first wave of the pandemic, indicating a higher number of infections than previously reported.
In September 2020, we tested 13,398 persons in Portugal for antibodies against severe acute respiratory syndrome coronavirus 2 by using a quota sample stratified by age and population density. We found a seroprevalence of 2.2%, 3-4 times larger than the official number of cases at the end of the first wave of the pandemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
